Galapagos NV
A biotechnology company focused on a rapid, decentralized cell therapy platform.
GLPG | BR
Overview
Corporate Details
- ISIN(s):
- BE0003818359
- LEI:
- 549300QKJ78IY0IOV655
- Country:
- Belgium
- Address:
- Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, 2800 Mechelen
- Website:
- https://www.glpg.com/
- Sector:
- Manufacturing
Description
Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-17 07:53 |
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
|
Dutch | PDF • 225.6 KB | ||
| 2025-10-17 07:53 |
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
|
English | PDF • 220.2 KB | ||
| 2025-10-02 06:48 |
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Busine…
|
English | PDF • 164.9 KB | ||
| 2025-10-02 06:48 |
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Busine…
|
Dutch | PDF • 164.9 KB | ||
| 2025-08-08 07:36 |
Galapagos Creates New Subscription Right Plan
|
Dutch | PDF • 203.1 KB | ||
| 2025-08-08 07:36 |
Galapagos Creates New Subscription Right Plan
|
English | PDF • 201.6 KB | ||
| 2025-08-07 00:00 |
Galapagos_PR_07082025_ENG.pdf
|
English | PDF • 208.3 KB | ||
| 2025-08-07 00:00 |
Galapagos_PR_07082025_NL.pdf
|
Dutch | PDF • 215.6 KB | ||
| 2025-08-07 00:00 |
1. Subscription Right Plan 2025 (B)_Board Report_7_180-7_191_ENG_FINAL_Website(…
|
English | PDF • 262.4 KB | ||
| 2025-08-07 00:00 |
1. Subscription Right Plan 2025 (B)_Board Report_7_180-7_191_NL_FINAL_Website(i…
|
Dutch | PDF • 379.8 KB | ||
| 2025-08-06 08:13 |
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) D…
|
Dutch | PDF • 101.6 KB | ||
| 2025-08-06 08:13 |
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) D…
|
English | PDF • 235.6 KB | ||
| 2025-08-06 07:30 |
Galapagos Press Release_RMAT Designation_GLPG5101_ENG_final.pdf
|
English | PDF • 235.6 KB | ||
| 2025-08-06 07:30 |
Galapagos Press Release_RMAT Designation_GLPG5101_NLfinal.pdf
|
Dutch | PDF • 290.7 KB | ||
| 2025-07-24 06:29 |
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Acc…
|
Dutch | PDF • 274.4 KB |
Automate Your Workflow. Get a real-time feed of all Galapagos NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Galapagos NV
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Galapagos NV via our API.
Peer Companies
